Supernus Pharmaceuticals, Inc. Overview
Pro stress-test →Supernus is a biopharmaceutical company that develops CNS disease treatments with a diverse portfolio of eight FDA-approved medications targeting neurological conditions including epilepsy, ADHD, Parkinson's disease, and migraine. The company recently acquired Sage Therapeutics, expanding its CNS treatment capabilities.
Strategic Profile
Pro stress-test →Supernus reported strong Q4 2025 revenue of $211.6 million, up 21.5% year-on-year, beating Wall Street expectations. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders with an emphasis on improving patient quality of life through innovative dosage forms and sustained-release formulations.
Competitive Landscape
Pro stress-test →Supernus develops and commercializes products for treatment of central nervous system (CNS) diseases in the United States through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company competes in the specialty pharmaceutical market alongside other CNS-focused players including Sage Therapeutics (now part of Supernus), Upsher-Smith Laboratories, and other neurological treatment developers.
Industry Context
Supernus Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Biopharmaceuticals - CNS Treatments.
Key facts
Founded: 2003 · Headquarters: Rockville, Maryland · Employees: 674 · Revenue: $662M · Market cap: $3.1B